TP53 mutation | Blood Cancers Today

TP53 mutation

Leah SherwoodMyelodysplastic Syndromes | November 16, 2022

A phase II, multicenter, open-label trial found that eprenetapopt plus azacitidine was well tolerated and safe.

Leah SherwoodMyelodysplastic Syndromes | February 2, 2023

A retrospective study showed that response rate and survival outcome are still modest for high-risk patients.

Leah SherwoodAcute Myeloid Leukemia | February 2, 2023

The presence of TP53-mutated MDS and AML with CK points to a single aggressive disease.

Leah SherwoodAcute Myeloid Leukemia | February 2, 2023

TP53-mutated AML and MDS-EB do not differ with respect to their clinical and molecular characteristics or survival outcomes.

Leah SherwoodMyelodysplastic Syndromes | November 15, 2022

Study finds BM CH was present in nearly two-thirds of BPDCN patients and particularly prevalent in elderly patients.

Leah SherwoodAcute Myeloid Leukemia | February 2, 2023

A phase III trial of magrolimab plus azacitidine versus standard of care in TP53-mutated AML is currently ongoing.

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer